Drugs / LY3884963
last change Nov 2020 re-read 2 minutes ago

LY3884963

Developed for
frontotemporal dementia
Investigated by
Eli Lilly and Company · Prevail Therapeutics

Trials 1 · a red edge is where a trial was stopped

2021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04408625 Nov 2020 → Nov 2029 expected frontotemporal dementia Prevail Therapeutics Active not recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as LY3884963 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04408625